PHARMACY POLICY STATEMENT
Marketplace

DRUG NAME	Xalkori (crizotinib)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Xalkori, originally approved by the FDA in 2011, is a small molecule tyrosine kinase inhibitor (TKI). As of 2022, it is indicated for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. It is also indicated to treat specific types of non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL).

IMTs are a rare but usually benign type of mesenchymal neoplasm that can be found in any age, although they most often develop in children or young adults. While these tumors typically affect the abdominal cavity, any area of the body can be affected. Surgery is the initial standard of care treatment, but surgery may not be possible in some cases, and tumors may recur after surgery. Malignant IMTs are uncommon, especially when ALK-positive.

Lung Cancer or Lymphoma

Any request for cancer must be submitted through NantHealth/Eviti portal.

CareSource considers Xalkori (crizotinib) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
09/28/2023	New policy for Xalkori created.

References:

1. Xalkori [prescribing information]. Pfizer Inc.; 2023.
2. Schöffski P, Kubickova M, Wozniak A, et al. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. *Eur J Cancer*. 2021;156:12-23. doi:10.1016/j.ejca.2021.07.016
3.